Conformia Software

About Conformia Software

Conformia Software, founded in 2000 by Neil Kataria and Kam Desai, established itself as a specialized provider of Product and Process Lifecycle Management (PPLM) solutions tailored for highly regulated process industries. The company was headquartered in Sunnyvale, California, and prior to its acquisition, had grown to 110 employees. The firm successfully raised $22.2 million over four funding rounds, backed by investors including Icon Ventures, Sequoia Capital, and Foundation Capital, which fueled its product development and market expansion efforts.

The company's core offering was its Development Operations Platform, an enterprise software solution designed to manage the entire lifecycle of drug development. This platform catered to life sciences companies, including biopharmaceutical and chemical sectors, by providing integrated modules for managing recipes, batch records, materials, and equipment. Its key function was to unify fragmented data across the development process—from initial design and experimentation in electronic lab notebooks to technology transfer for commercial manufacturing. This addressed a critical industry challenge of slow and costly product development by improving process knowledge, facilitating regulatory submissions, and ensuring compliance.

Conformia's business model was centered on selling its PPLM software to enterprise clients in the life sciences and other process manufacturing sectors, such as alcohol and beverages. The software was built on a service-oriented architecture, making it compatible with major database and application servers. In a significant milestone, Oracle acquired the intellectual property assets of Conformia Software on June 17, 2009. The strategic acquisition aimed to integrate Conformia's specialized technology into the Oracle Agile PLM solution. This integration created an end-to-end system for managing drug development, packaging, and commercialization, thereby enhancing Oracle's offerings for the pharmaceutical and biotechnology industries.